# EDGAR Filing Document

**Accession Number:** 0001393772
**File Stem:** 0001096906-26-000814
**Filing Date:** 2026-5
**Character Count:** 92984
**Document Hash:** 667f5f9d44259ee7a7790c2abb01be4b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001096906-26-000814.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0001096906-26-000814

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 61

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260515

**DATE AS OF CHANGE**: 20260515

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** WEED, INC.
- **CENTRAL INDEX KEY:** 0001393772
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 830452269
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-53727
- **FILM NUMBER:** 26987432

**BUSINESS ADDRESS:**
- **STREET 1:** 4920 N. POST TRAIL
- **CITY:** TUCSON
- **STATE:** AZ
- **ZIP:** 85750
- **BUSINESS PHONE:** 520-818-8582

**MAIL ADDRESS:**
- **STREET 1:** 4920 N. POST TRAIL
- **CITY:** TUCSON
- **STATE:** AZ
- **ZIP:** 85750

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** UNITED MINES INC
- **DATE OF NAME CHANGE:** 20070320

?xml version='1.0' encoding='ASCII'? budz_10q.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 10-Q**

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

**For the quarterly period ended <u>March 31, 2026</u>**

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________.

**Commission file number: <u>333-219922</u>**

---

| |
|:---|
| **WEED, INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Nevada** | **83-0452269**  |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |
| **4920 N. Post Trail** <br>**Tucson, AZ** | **85750** |
| (Address of principal executive offices) | (Zip Code) |

---

**<u>(520) 818-8582</u>**

Registrant's telephone number, including area code

---

| |
|:---|
| ________________________________<br>(Former address, if changed since last report) |
| __________________________________<br>(Former fiscal year, if changed since last report) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |

---

Securities registered pursuant to Section 12(g) of the Act:

**<u>Common Stock, $0.001 par value</u>**

(Title of class)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated Filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐&nbsp;&nbsp;&nbsp;&nbsp; No ☒.

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. As of May 14, 2026, there were 148,312,685 shares of common stock, $0.001 par value, issued and outstanding**.**

**WEED, INC.**

<u>**TABLE OF CONTENTS**</u>

---

| | | |
|:---|:---|:---|
| **[PART I - FINANCIAL INFORMATION](#P1)** | **[PART I - FINANCIAL INFORMATION](#P1)** | **3** |
| [ITEM 1](#i1) | [Consolidated Financial Statements](#i1) | 3 |
| [ITEM 2](#i2) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#i2) | 20 |
| [ITEM 3](#i3) | [Quantitative and Qualitative Disclosures About Market Risk](#i3) | 25 |
| [ITEM 4](#i4) | [Controls and Procedures](#i4) | 25 |
| **[PART II - OTHER INFORMATION](#p2)** | **[PART II - OTHER INFORMATION](#p2)** | **26** |
| [ITEM 1](#it1) | [Legal Proceedings](#it1) | 26 |
| [ITEM 1A](#it1a) | [Risk Factors](#it1a) | 26 |
| [ITEM 2](#it2) | [Unregistered Sales of Equity Securities and Use of Proceeds](#it2) | 26 |
| [ITEM 3](#it3) | [Defaults Upon Senior Securities](#it3) | 26 |
| [ITEM 4](#it4) | [Mine Safety Disclosures](#it4) | 26 |
| [ITEM 5](#it5) | [Other Information](#it5) | 26 |
| [ITEM 6](#it6) | [Exhibits](#it6) | 27 |

---

---

| |
|:---|
| 2 |
| *[**Table of Contents**](#toc)* |

---

**PART I - FINANCIAL INFORMATION**

This Quarterly Report includes forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements are based on management's beliefs and assumptions, and on information currently available to management. Forward-looking statements include the information concerning our possible or assumed future results of operations set forth under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations." Forward-looking statements also include statements in which words such as "expect," "anticipate," "intend," "plan," "believe," "estimate," "consider," or similar expressions are used.

Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties, and assumptions. Our future results and shareholder values may differ materially from those expressed in these forward-looking statements. Readers are cautioned not to put undue reliance on any forward-looking statements.

**ITEM 1 Consolidated Financial Statements**

The consolidated balance sheets as of March 31, 2026, (unaudited) and December 31, 2025, the consolidated statements of operations and comprehensive loss for the three months ended March 31, 2026 and 2025, the consolidated statement of changes in stockholders' equity (deficit) for the three months ended March 31, 2026 and 2025, and the consolidated statements of cash flows for the three months ending March 31, 2026 and 2025, follow. The unaudited interim financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. All such adjustments are of a normal and recurring nature.

---

| |
|:---|
| 3 |
| *[**Table of Contents**](#toc)* |

---

**WEED, INC. AND SUBSIDIARY**

**<u>CONSOLIDATED FINANCIAL STATEMENTS</u>** 

**March 31, 2026**

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **Page No.** |
| **CONSOLIDATED FINANCIAL STATEMENTS** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;[Unaudited Consolidated Balance Sheets](#bs) | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Unaudited Consolidated Statements of Operations and Comprehensive Loss](#soo) | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Unaudited Consolidated Statements of Changes in Stockholders' Equity (Deficit)](#eqt) | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Unaudited Consolidated Statements of Cash Flows](#cf) | 8 |

---

---

| |
|:---|
| 4 |
| *[**Table of Contents**](#toc2)* |

---

---

| |
|:---|
| **WEED, INC.** |
| <u>**CONSOLIDATED BALANCE SHEETS**</u> |
| **(Unaudited)** |

---

---

| | | |
|:---|:---|:---|
|  | **(Unaudited)**<br>**March 31,**<br>**2026** | **December 31,**<br>**2025** |
| ASSETS |  |  |
| CURRENT ASSETS: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash | $1795 | $33130 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 6675 | 10680 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current asset | 3895 | 3895 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL CURRENT ASSETS | 12365 | 47705 |
| &nbsp;&nbsp;&nbsp;&nbsp;Land | 258319 | 258319 |
| &nbsp;&nbsp;&nbsp;&nbsp;Building | 218681 | 218681 |
| &nbsp;&nbsp;&nbsp;&nbsp;Computers & Equipment | 147771 | 147771 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, gross | 624771 | 624771 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Accumulated depreciation | (153275) | (148304) |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | 471496 | 476467 |
| &nbsp;&nbsp;&nbsp;&nbsp;Grower License | 667 | 667 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trademark | 50000 | 50000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, gross | 50667 | 50667 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Accumulated amortization | (20334) | (19684) |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net | 30333 | 30983 |
| &nbsp;&nbsp;&nbsp;&nbsp;ROU asset | 1519 | 4751 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL ASSETS | $515713 | $559906 |
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) |  |  |
| CURRENT LIABILITIES |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $182943 | $179914 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expense | 130800 | 111300 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued officer compensation | 414750 | 369750 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued interest | 42326 | 33414 |
| &nbsp;&nbsp;&nbsp;&nbsp;Notes payable, related parties | 534749 | 502985 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset retirement obligation | 35800 | 35800 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease liability | 1519 | 4751 |
| &nbsp;&nbsp;&nbsp;&nbsp;Due to officer | 10353 | 10353 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL CURRENT LIABILITIES | 1353240 | 1248267 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL LIABILITIES | 1353240 | 1248267 |
| STOCKHOLDERS' EQUITY (DEFICIT) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value, 200,000,000 authorized, 148,312,685 and 147,432,685 issued and outstanding, respectively | 148313 | 147433 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 85078651 | 85050643 |
| &nbsp;&nbsp;&nbsp;&nbsp;Subscription payable | 386250 | 386250 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (86450741) | (86275485) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation | - | 2798 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL STOCKHOLDERS' EQUITY | (837527) | (688361) |
| TOTAL LIABILITIES & STOCKERHOLDERS' EQUITY | $515713 | $559906 |

---

The accompanying notes are an integral part of the consolidated financial statements

---

| |
|:---|
| 5 |
| *[**Table of Contents**](#toc2)* |

---

---

| |
|:---|
| **WEED, INC.** |
| <u>**CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**</u> |
| **(Unaudited)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the Three Months** | **For the Three Months** |
|  | **Ended March 31,** | **Ended March 31,** |
|  | **2026** | **2025** |
| REVENUE | $- | $- |
| COST OF GOODS SOLD | - | - |
| GROSS PROFIT | - | - |
| OPERATING EXPENSES |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses | 67833 | 383268 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional fees | 90500 | 45847 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation & amortization | 5622 | 5622 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 163955 | 434737 |
| NET OPERATING LOSS | (163955) | (434737) |
| OTHER INCOME (EXPENSE) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (14099) | (5718) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation gain on dissolution of subsidiary | 2798 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;TOTAL OTHER INCOME (EXPENSE) | (11301) | (5718) |
| NET LOSS BEFORE INCOME TAX | (175256) | (440455) |
| INCOME TAX EXPENSE |  |  |
| NET LOSS | (175256) | (440455) |
| OTHER COMPREHENSIVE INCOME (LOSS) | - | 75 |
| COMPREHENSIVE LOSS | $(175256) | $(440380) |
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Outstanding - basic and fully diluted | 147510907 | 132432685 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss per share - basic and fully diluted | $(0.001) | $(0.003) |

---

The accompanying notes are an integral part of the consolidated financial statements

---

| |
|:---|
| 6 |
| *[**Table of Contents**](#toc2)* |

---

---

| |
|:---|
| **WEED, INC.** |
| <u>**CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)**</u> |
| **For the Three Months ended March 31, 2025** |
| **(Unaudited)** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | | |
|  | **Shares** | **Amount** | **Additional**<br>**Paid-In**<br>**Capital** |<br>**Subscriptions**<br>**Payable** |<br>**Accumulated**<br>**Deficit** | **Accumulated**<br> **Other**<br>**Comprehensive** | **Total**<br>**Stockholders'**<br>**Equity** |
| **Balance, December 31, 2024** | 125432685 | $125433 | $84166601 | $386250 | $(84903279) | $3989 | $(221006) |
| Common stock sold for cash | - | - | - | - | - | - | - |
| Common stock issued for services | 10500000 | 10500 | 304500 | - | - | - | 315000 |
| Imputed Interest on RP Loans | - | - | 300 | - | - | - | 300 |
| Net Loss | - | - | - | - | (440455) | - | (440455) |
| Other comprehensive income, net | - | - | - | - | - | (75) | (75) |
| **Balance, March 31, 2025** | 135932685 | $135933 | $84471401 | $386250 | (85343734) | 3914 | $(346236) |

---

**For the Three Months ended March 31, 2026**

**(Unaudited)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | | |
|  | **Shares** | **Amount** | **Additional**<br>**Paid-In**<br>**Capital** |<br>**Subscriptions**<br>**Payable** |<br>**Accumulated**<br>**Deficit** | **Accumulated**<br>**Other**<br>**Comprehensive** | **Total**<br>**Stockholders'**<br>**Equity** |
| **Balance, December 31, 2025** | 147432685 | $147433 | $85050643 | $386250 | $(86275485) | $2798 | $(688361) |
| Common stock sold for cash |  |  |  |  |  |  |  |
| Common stock issued for services | 880000 | 880 | 25520 |  |  |  | 26400 |
| Imputed Interest on RP Loans |  |  | 2488 |  |  |  | 2488 |
| Net Loss |  |  |  |  | (175256) |  | (175256) |
| Release of accumulated foreign currency translation loss on dissolution of subsidiaries | - | - | - | - | - | (2798) | (2798) |
| **Balance, March 31, 2026** | 148312685 | $148313 | $85078651 | $386250 | $(86450741) | $- | $(837527) |

---

The accompanying notes are an integral part of the consolidated financial statements

---

| |
|:---|
| 7 |
| *[**Table of Contents**](#toc2)* |

---

---

| |
|:---|
| **WEED, INC.** |
| <u>**CONSOLIDATED STATEMENTS OF CASH FLOWS**</u> |
| **(Unaudited)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the Three** | **For the Three** |
|  | **Months Ended March 31,** | **Months Ended March 31,** |
|  | **2026** | **2025** |
| CASH FLOWS FROM OPERATING ACTIVITIES |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(175256) | $(440455) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile to net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 5622 | 5622 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Debt discount amortization | 2564 | 2563 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Imputed Interest on RP Loans | 2488 | 300 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estimated fair value of stock based compensation |  | 300000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estimated fair value of shares issued for services | 26400 | 15000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decrease (increase) in assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and deposits | 4005 | (1980) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts Payable | 3028 | 2656 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 73412 | 44456 |
| &nbsp;&nbsp;&nbsp;&nbsp;NET CASH USED IN OPERATING ACTIVITIES | (57737) | (71838) |
| CASH FLOWS FROM FINANCING ACTIVITIES |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase in due to officer |  | 700 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from notes payable – related party | 30000 | 45000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repayments on notes payable – related party | (800) | (130000) |
| NET CASH USED IN FINANCING ACTIVITIES | 29200 | (84300) |
| NET CHANGE IN CASH | (28537) | (156138) |
| EFFECT OF EXCHANGE RATE ON CASH | (2798) | (75) |
| CASH, BEGINNING OF PERIOD | 33130 | 159355 |
| CASH, END OF PERIOD | $1795 | $3142 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION |  |  |
| Cash paid during the periods ended December 31: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes | $- |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest paid | $135 | $298 |

---

The accompanying notes are an integral part of the consolidated financial statements

---

| |
|:---|
| 8 |
| *[**Table of Contents**](#toc2)* |

---

 **WEED, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**March 31, 2026**

**(Unaudited)**

**Note 1 – Nature of Business and Significant Accounting Policies**

<u>Nature of Business</u>

WEED, Inc. (the "Company"), (formerly United Mines, Inc.) was incorporated under the laws of the State of Arizona on August 20, 1999 ("Inception Date") as Plae, Inc. to engage in the exploration of gold and silver mining properties. On November 26, 2014, the Company was renamed from United Mines, Inc. to WEED, Inc. and was repurposed to pursue a business involving the purchase of land, and building Commercial Grade "Cultivation Centers" to consult, assist, manage & lease to Licensed Dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana sector. The Company's plan is to become a True "Seed-to-Sale" company providing infrastructure, financial solutions and real estate options in this new emerging market. The Company, under United Mines, was formerly in the process of acquiring mineral properties or claims located in the State of Arizona, USA. The name was previously changed on February 18, 2005 to King Mines, Inc. and then subsequently changed to United Mines, Inc. on March 30, 2005. The Company trades on the OTC Pink Sheets under the stock symbol: BUDZ.

On April 20, 2017, the Company acquired Sangre AT, LLC, a Wyoming company doing business as Sangre AgroTech. ("Sangre"). Sangre is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. No work is being conducted now until further funds are available.

On May 2, 2022, the Company acquired Hempirical Genetics, LLC, a Arizona company.

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.

The Company has a calendar year end for reporting purposes.

<u>Basis of Presentation</u>

The accompanying consolidated balance sheet at December 31, 2025, has been derived from audited consolidated financial statements and the unaudited condensed consolidated financial statements as of March 31, 2026 (the "financial statements"), have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and related footnotes. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments), have been made which are necessary for a fair financial statement presentation. The consolidated financial statements include all material adjustments (consisting of normal recurring accruals) necessary to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. Interim results are not necessarily indicative of results for a full year.

<u>Principles of Consolidation</u>

The accompanying consolidated financial statements include the accounts of the following entities, all of which are under common control and ownership:

---

| | | | |
|:---|:---|:---|:---|
| <br>**Name of Entity** | **State of**<br>**Incorporation** | <br>**Relationship (1&3)** | **Abbreviated**<br>**Reference** |
| WEED, Inc. | Nevada | Parent | WEED |
| Sangre AT, LLC (2) | Wyoming | Subsidiary | Sangre |
| Hempirical Genetics, LLC (3) | Arizona | Subsidiary | Hempirical Generics |

---

(1) Sangre is a wholly-owned subsidiary of WEED, Inc.

(2) Sangre AT, LLC is doing business as Sangre AgroTech.

(3) Hempirical Genetics, LLC is a wholly-owned subsidiary of WEED, Inc.

---

| |
|:---|
| 9 |
| *[**Table of Contents**](#toc2)* |

---

**Note 1 – Nature of Business and Significant Accounting Policies (continued)**

<u>Principles of Consolidation (continued)</u>

The consolidated financial statements herein contain the operations of the wholly-owned subsidiary listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company, WEED and subsidiaries will be collectively referred to herein as the "Company", or "WEED". The Company's headquarters are located in Tucson, Arizona and its operations are primarily within the United States.

These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.

<u>Use of Estimates</u>

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

<u>Fair Value of Financial Instruments</u>

Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company's financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments.

<u>Impairment of Long-Lived Assets</u>

Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations.

<u>Basic and Diluted Loss Per Share</u>

The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an "as if converted" basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

<u>Stock-Based Compensation</u>

Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values.

<u>Revenue Recognition</u>

The Company is using the revenue recognition standard ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)", and using the cumulative effect (modified retrospective) approach. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings at the date of initial application. No cumulative-effect adjustment in retained earnings was recorded as the Company has no historical revenue. The impact of the adoption of the new standard was not material to the Company's consolidated financial statements. The Company did not earn revenue during the periods ended March 31, 2026 and 2025. When the Company earns revenue, it will be recognized in accordance with FASB ASC 606 – Revenue from Contracts with Customers.

The primary change under the new guidance is the requirement to report the allowance for uncollectible accounts as a reduction in net revenue as opposed to bad debt expense, a component of operating expenses. The adoption of this guidance did not have an impact on our condensed consolidated financial statements, other than additional financial statement disclosures. The guidance requires increased disclosures, including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.

The Company operates as one reportable segment.

---

| |
|:---|
| 10 |
| *[**Table of Contents**](#toc2)* |

---

**Note 1 – Nature of Business and Significant Accounting Policies (continued)**

<u>Revenue Recognition (continued)</u>

Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company will defer any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales have not yet commenced.

<u>Advertising and Promotion</u>

All costs associated with advertising and promoting products are expensed as incurred. The Company recognized $2,520 and $55 of advertising and promotion costs for the three months ended March 31, 2026 and 2025.

<u>Asset Retirement Obligations</u>

The Company acquired a gas well on February 23, 2023, with a cost of $41,400. We are required to record a liability for the present value of our asset retirement obligation ("ARO") to plug and abandon inactive-non-producing wells, facilities, and equipment, and to restore the land at the end of oil production operations. As a result, we accrued the full value of the cost amounting to $35,800 for plug and abandon non-operating well on the consolidated balance sheet as of March 31, 2026 and December 31, 2025.

<u>Foreign Currency Transactions</u>

Expenses are translated at the exchange rates in effect at the date of the transaction. Foreign currency denominated payables are translated at the rates of exchange at the balance sheet date. The resulting transaction gains and losses are recorded in the statement of income in the period incurred.

Assets and liabilities of those operations are translated at exchange rates in effect at the balance sheet date. Income and expenses are translated using the exchange rates on the transaction date for the reporting period. Translation adjustments, if any, are reported as a separate component of accumulated other comprehensive income (loss). For all significant foreign operations, the functional currency is the local currency.

During the three months ended March 31, 2026, the Company completed the dissolution of certain non-material foreign subsidiaries, including WEED Hong Kong Ltd. and WEED Australia Ltd. In connection with the dissolution, the related cumulative foreign currency translation adjustment of $2,798 was reclassified from accumulated other comprehensive loss into earnings and recognized in other income (expense). For the three months ended March 31, 2025, foreign currency transaction gain was $75.

<u>Recently Adopted Accounting Standards</u>

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segments expenses. The amendments require that a public entity disclose, on an annual and interim basis, an amount for other segment items by reportable segment and a description of its composition. The other segment items category is the difference between segment revenue less the segment expenses disclosed under the significant expense principle and each reported measure of segment profit or loss. The amendments improve financials reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities. The Company adopted ASU No. 2023-07 for our fiscal year 2024 annual financial statements and interim financial statements thereafter and have applied this standard retrospectively for all period presented in the consolidated financial statements. See Note 11 for more details on the Company's segment information.

---

| |
|:---|
| 11 |
| *[**Table of Contents**](#toc2)* |

---

**Note 2 – Going Concern**

As shown in the accompanying financial statements, the Company has no revenues, incurred net losses from operations resulting in an accumulated deficit of $86,450,741 and negative working capital $1,340,875 at March 31, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management is actively pursuing new products and services to begin generating revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern.

The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company's ability to continue as a going concern. The financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

**Note 3 – Related Party**

<u>Notes Payable</u>

From time to time, the Company has received short-term loans from officers and directors as disclosed in Note 7 below. The Company has a total of $534,749 and $502,985 of notes payable on the consolidated balance sheet as of March 31, 2026 and December 31, 2025, respectively.

From January 2022 to March 31, 2022, the Company received loans of $4,000 and $500,000 from Nicole Breen and Glenn Martin, respectively. The $500,000 loan from Glenn Martin replaced the $300,000 loan. From January 2023 to March 31, 2023, the Company paid off the remaining balance of the loan from Nicole Breen that was originally $37,500. From April 2023 to June 30, 2023, the Company received $50,000 from Nicole Breen. From July 2023 to September 30, 2023, the Company paid off Glenn Martin's loan of $500,000 and Nicole Breen's loan of $50,000. From July 2024 to September 30, 2024, the Company received $10,000 from Glenn Martin. From September 2024 to December 31, 2024, the Company received $300,000 from Glenn Martin and paid off Glenn Martin's loan of $5,000. From January 2025 to December 31, 2025, the Company received loans of $162,000 and $37,403 from Glenn Martin and Nicole Breen, respectively, and paid off $130,000 of Glenn Martin's loan. From January 2026 to March 31, 2026, the Company received $30,000 from Glenn Martin and paid off $800 of Nicole Breen's loan.

On May 2, 2022, the Company acquired the Hempirical Genetics, LLC from Jeffrey Miller, and then Jeffrey Miller became the executive officer of WEED, Inc. Based on the agreement, the Company owed Jeffrey Miller $120,000 as of June 30, 2023.

On July 1, 2022, Patrick Brodnik signed executive employee agreement with the Company, and become one of the related parties since that. On various dates during the third quarter 2022, the Company received advance of $3,661 from Patrick Brodnik at no interest. From April 2024 to June 2024, the Company paid off the advance of $3,661.

---

| |
|:---|
| 12 |
| *[**Table of Contents**](#toc2)* |

---

**Note 3 – Related Party (continued)**

<u>Services</u>

Nicole M. Breen receives $8,000 a month in cash compensation for her services rendered to the Company.

Glenn E. Martin receives $7,000 a month in cash compensation for his services rendered to the Company.

<u>Accrued Expense</u>

A total of $71,400 and $66,900 of accrued expenses related to rent was unpaid and outstanding as of March 31, 2026 and December 31, 2025, respectively.

<u>Accrued Compensation</u>

A total of $414,750 and $369,750 of officer compensation was unpaid and outstanding as of March 31, 2026 and December 31, 2025, respectively.

**Note 4 – Fair Value of Financial Instruments**

Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value.

The Company has certain financial instruments that must be measured under the new fair value standard. The Company's financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows:

Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability.

The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of March 31, 2026 and December 31, 2025, respectively:

**<u>Fair Value Measurements at December 31, 2025</u>**

---

| | | | |
|:---|:---|:---|:---|
|  | **Level 1** | **Level 2** | **Level 3** |
| **Assets** |  |  |  |
| Cash | $33130 | $- | $- |
| Intangible assets, net | $- | $30983 | $- |
| Total assets | $33130 | $30983 | $- |
| **Liabilities** |  |  |  |
| Notes payable, related parties | $- | $502985 | $- |
| Notes payable | $- | $- | $- |
| Total liabilities | $- | $502985 | $- |

---

**<u>Fair Value Measurements at March 31, 2026</u>**

---

| | | | |
|:---|:---|:---|:---|
|  | **Level 1** | **Level 2** | **Level 3** |
| **Assets** |  |  |  |
| Cash | $1795 | $- | $- |
| Intangible assets, net | $- | $30333 | $- |
| Total assets | $1795 | $30333 | $- |
| **Liabilities** |  |  |  |
| Notes payable, related parties | $- | $534749 | $- |
| Notes payable | $- | $- | $- |
| Total liabilities | $- | $534749 | $- |

---

---

| |
|:---|
| 13 |
| *[**Table of Contents**](#toc2)* |

---

**Note 4 – Fair Value of Financial Instruments (continued)**

The fair values of our related party debts are deemed to approximate book value and are considered Level 2 inputs as defined by ASC Topic 820-10-35.

There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the three months ended March 31, 2026 and the year ended December 31, 2025.

**Note 5 – Property and Equipment**

Property and equipment consist of the following at March 31, 2026 and December 31, 2025, respectively:

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| Office equipment | $8666 | $8666 |
| Furniture & Fixtures | 5479 | 5479 |
| Lab equipment | 133626 | 133626 |
| Land | 258319 | 258319 |
| Property | 218681 | 218681 |
| Property and equipment, gross | 624771 | 624771 |
| Less accumulated depreciation | (153275) | (148304) |
| Property and equipment**,** net | $471496 | $476467 |

---

Depreciation expense totaled $4,972 and $4,972 for the three months ended March 31, 2026 and 2025, respectively.

**Note 6 – Intangible Assets**

<u>Intangibles</u>

In accordance with FASB ASC 350, "Intangibles-Goodwill and Other", the Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset's carrying amount may not be recoverable. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The US and Europe trademarks were acquired for $40,000 and $50,000, respectively, for the year ended December 31, 2018. Trademarks are initially measured based on their fair value and amortized by 10 and 25 years.

Acquisition intangible assets arising out of the acquisition of Hempirical Genetics, LLC. That should, in accordance with GAAP, be classified as intangibles, include goodwill.

On March 31, 2026 and December 31, 2025, intangibles consists of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| Trademark | 50000 | 50000 |
| Grower License | 667 | 667 |
| Less: Accumulated amortization | (20334) | (19684) |
| Total other intangibles, Net | 30333 | 30983 |

---

Amortization expense totaled $650 and $650 for the three months ended March 31, 2026 and 2025, respectively.

---

| |
|:---|
| 14 |
| *[**Table of Contents**](#toc2)* |

---

**Note 7 – Notes Payable, Related Parties**

Notes payable, related parties consist of the following at March 31, 2026 and December 31, 2025, respectively:

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| On April 12, 2010, the Company received an unsecured, non-interest-bearing loan in the amount of $2,000, due on demand from Robert Leitzman. Interest is being imputed at the Company's estimated borrowing rate, or 10% per annum. The largest aggregate amount outstanding was $2,000 during the periods ended December 31, 2019 and December 31, 2018. Mr. Leitzman owns less than 1% of the Company's common stock, however, the Mr. Leitzman is deemed to be a related party given the non-interest-bearing nature of the loan and the materiality of the debt at the time of origination. | $2000 | $2000 |
| Over various dates in 2011 and 2012, the Company received unsecured loans in the aggregate amount of $10,000, due on demand, bearing interest at 10%, from Sandra Orman. The largest aggregate amount outstanding was $10,000 during the periods ended December 31, 2019 and December 31, 2018. Mrs. Orman owns less than 1% of the Company's common stock, however, Mrs. Orman is deemed to be a related party given the nature of the loan and the materiality of the debt at the time of origination. | $10000 | $10000 |
| During 2024 and 2025, the Company received advances totaling $472,000 from Glenn Martin and $37,403 from Nicole Breen, bearing interest at 5% and 12%, respectively. During 2025, the Company made payments totaling $135,000 to Glenn Martin. During the three months ended March 31, 2026, the Company received additional advances of $30,000 from Glenn Martin, bearing interest at 12%, and made a payment of $800 to Nicole Breen. | $403603 | $374403 |
| On May 2, 2022, the company acquired Hempirical Genetics, LLC with a note payable to the executive officer Jeffrey Miller with no interest. Payments of $0 and $25,000 were made toward the note in 2025 and 2024, respectively. | $120000 | $120000 |

---

---

| |
|:---|
| 15 |
| *[**Table of Contents**](#toc2)* |

---

**Note 7 – Notes Payable, Related Parties (continued)**

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br>**2026** | **December 31,**<br>**2025** |
| Notes payable, related parties | $535603 | $506403 |
| Less: Loan fee, net of amortization | $(854) | $(3418) |
| Notes payable, related parties | $534749 | $502985 |

---

The Company recorded interest expense in the amount of $14,099 and $5,718 for the three months ended March 31, 2026 and 2025, respectively, including debt amortization expense of $2,564 and $2,563 and imputed interest expense in the amount of $2,488 and $300 during such periods related to notes payable, related parties.

**Note 8 – Commitments and Contingencies**

<u>Operating Leases</u>

We account for our lease under ASC 842. Under this guidance, arrangements meeting the definition of a lease are classified as operating and are recorded on the consolidated balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term.

The rate implicit in lease is not readily determinable, and we therefore use incremental borrowing rate to determine the present value of the lease payments. The incremental borrowing rate used to determine the initial value of right-of-use ("ROU") assets and lease liabilities during the period ended March 31, 2026, was 5.0%.

In May, 2022, we entered into a lease agreement of a hemp drying facility in Huachuca City, Arizona for $1,200 per month. The lease term began May 2, 2022 and ends May 2, 2026. As of March 31, 2026, we had lease liability of $1,519, and ROU assets of $1,519.

---

| |
|:---|
| 16 |
| *[**Table of Contents**](#toc2)* |

---

**Note 8 – Commitments and Contingencies (continued)**

<u>Legal Proceedings</u>

The Company may be subject to legal proceedings and claims arising from contracts or other matters from time to time in the ordinary course of business. Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its financial position, results of operations or liquidity.

**Note 9 – Stockholders' Equity**

<u>Preferred Stock</u>

On December 5, 2014, the Company amended the Articles of Incorporation, pursuant to which 20,000,000 shares of "blank check" preferred stock with a par value of $0.001 were authorized. No series of preferred stock has been designated to date.

<u>Common Stock</u>

On December 5, 2014, the Company amended the Articles of Incorporation and increased the authorized shares to 200,000,000 shares of $0.001 par value common stock.

***2026 Common Stock Activity***

<u>Common Stock Sales (2026)</u>

No shares of common stock were sold during the three months ended March 31, 2026.

<u>Common Stock Issued for Services (2026)</u>

During the period ended March 31, 2026, 880,000 shares of common stocks valued at $26,400 were issued for the services.

<u>Common Stock Cancellations</u>

No shares of common stock were cancelled during the three months ended March 31, 2026.

***2025 Common Stock Activity***

<u>Common Stock Sales (2025)</u>

No shares of common stock were sold during the three months ended March 31, 2025.

<u>Common Stock Issued for Services (2025)</u>

During the quarter ended March 31, 2025, 10,000,000 shares of common stocks valued at $300,000 were issued for the services.

During the quarter ended March 31, 2025, the Company agreed to issue an aggregate of 500,000 shares to consultants for services performed. The total fair value of common stock was $15,000 based on the closing price of the Company's common stock earned on the measurement date.

<u>Common Stock Cancellations</u>

No shares of common stock were cancelled during the three months ended March 31, 2025.

---

| |
|:---|
| 17 |
| *[**Table of Contents**](#toc2)* |

---

**Note 9 – Stockholders' Equity (continued)**

**Common Stock Warrants and Options**

***2026 Common Stock Warrant Activity***

<u>Common Stock Warrants Granted (2026)</u>

No common stock warrants were granted during the quarter ended March 31, 2026.

<u>Warrants Exercised (2026)</u>

No warrants were exercised during the quarter ended March 31, 2026.

***2025 Common Stock Warrant Activity***

<u>Common Stock Warrants Granted (2025)</u>

No common stock warrants were granted during the three months ended March 31, 2025.

<u>Warrants Exercised (2025)</u>

No warrants were exercised during the three months ended March 31, 2025.

<u>Warrants Exercised (2025)</u>

The stock option will expire on the tenth anniversary of the granted date, which is February 1, 2028. As of March 31, 2026, the stock option will expire in 22 months.

A summary of the Company's stock option activity and related information is as follows:

---

| | | |
|:---|:---|:---|
|  | **For the year ended**<br>**December 31, 2025** | **For the year ended**<br>**December 31, 2025** |
|  | **Number of**<br>**Shares** | **Average**<br>**Price** |
| Outstanding at the beginning of period | 6000000 | $10.55 |
| Granted |  |  |
| Exercised/Expired/Cancelled | - | - |
| Outstanding at the end of period | 6000000 | $10.55 |
| Exercisable at the end of period | 6000000 | $10.55 |

---

---

| | | |
|:---|:---|:---|
|  | **For the quarter ended**<br>**March 31, 2026** | **For the quarter ended**<br>**March 31, 2026** |
|  | **Number of**<br>**Shares** | **Average**<br>**Price** |
| Outstanding at the beginning of period | 6000000 | $10.55 |
| Granted |  |  |
| Exercised/Expired/Cancelled | - | - |
| Outstanding at the end of period | 6000000 | $10.55 |
| Exercisable at the end of period | 6000000 | $10.55 |

---

---

| |
|:---|
| 18 |
| *[**Table of Contents**](#toc2)* |

---

**Note 10 – Income Tax**

The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provided that deferred tax assets and liabilities, are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences.

For the three months ending March 31, 2026 and year ended December 31, 2025, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. On March 31, 2026 and December 31, 2025, the Company had approximately $175,256 and $1,372,173 of loss of federal net operating losses, respectively. The net operating loss carry forwards, if not utilized, will begin to expire in 2031.

The components of the Company's deferred tax assets are as follows:

---

| | |
|:---|:---|
|  | **March 31,** <br>**2026** |
| Deferred tax assets: |  |
| Net operating loss carry forward as of 12/31/2025 | $19783456 |
| Estimate Tax Loss March 31, 2026 | 175256 |
| **NOL Carry Forward Cumulative as of 3/31/2026** | 19958711 |
| Statutory Tax Rate | 21% |
| Deferred Tax Asset | 4191329 |
| Valuation | (4191329) |
| Net Deferred Tax Asset | 0 |

---

Based on the available objective evidence, including the Company's history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at March 31, 2026 and December 31, 2025, respectively.

**Note 11 – Segment Information**

We operate in one reportable segment, which is the purchase of land, and building Commercial Grade "Cultivation Centers" to consult, assist, manage and lease to Licensed Dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana sector. The Company's CODM includes the chief executive officer and chief financial officer. The chief operating decision maker ("CODM") regularly review and use the consolidated net loss, as reported on our Consolidated Statements of Operations and Comprehensive Loss in evaluating the overall performance of our single reporting segment. The CODM also reviews total assets as reported in the consolidated financial statements when allocating resources. As a result, the Company has determined that it has only one reportable segment. The measure of segment assets is represented as total assets presented on our accompanying balance sheets.

Although the Company has not generated revenue during the reporting period, it continues to incur expenses related to research and development, general and administrative activities, and other operational costs. The CODM uses these expense categories to assess the Company's performance and allocate resources.

The accounting policies of the single segment are the same as those described in the summary of significant accounting policies. There have been no significant changes in measurement methods from the prior year.

Geographically, we have no assets in a foreign country requiring separate disclosure.

The following table provides the significant expenses that management used to manage our one reportable segment:

---

| | | |
|:---|:---|:---|
|  | **March 31,** <br>**2026** | **March 31,** <br>**2025** |
| General and administrative expenses | 67833 | 383268 |
| Professional fees | 90500 | 45847 |
| Depreciation and amortization | 5622 | 5622 |
| Total operating expenses | 163955 | 434737 |

---

The table above presents the Company's single operating segment results and reconciles the segment expenses reviewed by the CODM to consolidated net loss as reported in the Consolidated Statements of Operations and Comprehensive Loss.

**Note 12 – Subsequent Events**

We have evaluated subsequent events through the filing date of this Form 10-K and determined that no subsequent events have occurred that would require recognition in the consolidated financial statements or disclosures in the notes thereto.

---

| |
|:---|
| 19 |
| *[**Table of Contents**](#toc2)* |

---

**ITEM 2 Management's Discussion and Analysis of Financial Condition and Results of Operations.**

**Disclaimer Regarding Forward Looking Statements**

Our Management's Discussion and Analysis or Plan of Operations contains not only statements that are historical facts, but also statements that are forward-looking. Forward-looking statements are, by their very nature, uncertain and risky. These risks and uncertainties include international, national and local general economic and market conditions; demographic changes; our ability to sustain, manage, or forecast growth; our ability to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; and other risks that might be detailed from time to time in our filings with the Securities and Exchange Commission.

Although the forward-looking statements in this Quarterly Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.

**<u>Overview</u>**

WEED, Inc. (the "Company") is a multi-national bio-pharmaceutical and real estate holding company. Our mission is to lead the development and application of cannabis-derived compounds for medical and industrial use. During fiscal 2025, the Company focused on asset preservation and the modernization of its business model, which included streamlining international operations and exploring the integration of blockchain and AI technologies within the regulated cannabis ecosystem.

Our first business opportunity was, and continues to be, through our wholly-owned subsidiary, Sangre AT, LLC ("Sangre"), where we are focused on the development and application of cannabis-derived compounds for the treatment of human disease and animal ailments. To that end Sangre, was working on a planned five-year Cannabis Genomic Study to complete a genetic blueprint of the Cannabis plant genus, by creating a global genomic classification of the entire plant. Sangre completed a 1-2 year Pilot Study in 2017 & 2018 at the University of Texas-Galveston through Industrial Metagenomics at a cost of nearly $1 million USD. Sangre completed the pilot study with 30 cultivars from strains collected worldwide that included 30 strains (twenty-four female and six male). These results are highly proprietary and the basis of future studies to come. We need to raise additional funds to continue the next steps in our Cannabis Genomic Study.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On May 14th, 2018, the 70th Anniversary of the statehood of Israel, WEED formed its wholly owned subsidiary, WEED Israel Cannabis Ltd., with the goal of completing and adding to the noted studies above. As such, WEED Israel worked with the Hebrew University in Jerusalem and with the top scientists globally in the field of Cannabis & hemp. To that effect, WEED Israel looked to conduct clinical trials and product development that would be the quality and acceptability of the FDA in the United States. Due to current laws and conditions in the USA, all research results and product development for both Pharma & Non-Pharma products, cannot be introduced the United States marketplace. Since starting in 2018, the USA has made vast improvements and advancements in the legalization of both Cannabis and hemp. As of the end of 2021 there are 37 States that have approved a State level medical cannabis and hemp programs, along with the District of Colombia. In addition, there are 17 States that have implemented or approved the "Adult Use" i.e. recreational psychoactive aspects of high THC usage of cannabis.

---

| |
|:---|
| 20 |
| *[**Table of Contents**](#toc)* |

---

conjunction with WEED Israel Cannabis Ltd., we made arrangements with Professor Elka Touitou to be available to be the head of WEEDs Israeli Advisory Board to lead and assist us with clinical trials in cannabis & hemp research studies in Israel. Professor Touitou was the Head of the Innovative Dermal, Transdermal and Transmucosal Delivery Lab at the Institute of Drug Research, The School of Pharmacy, HUJ, now retired but still has HUJ clinical trial & independent studies/lab privileges. Professor Touitou is an internationally renowned authority in the field of drug delivery and design of new technologies for efficient administration of drugs and development of new products. Professor Touitou has been involved in Cannabinoid research since 1988 at The Hebrew University of Jerusalem, (HUJ) Jerusalem, Israel. Previously, WEED was in the process of buying Professor Touitou's various patents to include the bioavailability aspects of the cannabaceae plant. However, after expending over $500,000 USD to acquire the Professor Touitou's patents, we had to terminate the agreement in 2019 due to the downturn of the Cannabis marketplace, and specifically as to public cannabis companies, which could not be resumed due to the Covid pandemic that was/is still ongoing globally. We have kept in constant contact with Professor Touitou thru our Managing Director of WEED Israel, Mr. Elliot Kwestel. As of 2022, Dr. Touitou still has interest in working with WEED to complete the purchase of her patents and begin clinical trials upon proper funding. WEED looks to achieve that funding thru offerings of our securities.

**<u>Key Material Events of 2025</u>**

*Research and Intellectual Property Development*

The Company continues to integrate assets from the Hempirical Genetics, LLC acquisition. This includes a proprietary seedbank of over 250 cannabis and hemp strains, featuring rare Landrace varieties such as Panama Red and Acapulco Gold. Throughout 2025, management focused on cataloging these genetics to support future pharmaceutical research and consumer product strategies. These genetic assets are currently carried at a cost basis on our balance sheet, though management believes they represent significant long-term strategic value as the federal regulatory environment for cannabis evolves.

*Strategic Technology Initiatives*

In December 2025, the Company entered into a strategic partnership with Remergify, Inc. to evaluate the development of a digital asset ecosystem. This project aims to address banking and supply chain challenges through the potential launch of WEEDCoin and BUDZCoin. These initiatives are currently in the early development phase. The Company's ability to successfully launch these digital assets is subject to the availability of capital and the complex, evolving regulatory framework governing digital assets and decentralized finance.

*Real Estate Assets and Infrastructure*

A cornerstone of the Company's stability is its long-term real estate holdings. Management continues to maintain and market its high-value land assets, notably the "Four Winds of Lake Erie" property in Portland, New York. This 44-acre parcel, featuring significant lake frontage, represents a key "hard asset" that distinguishes the Company from peers in the microcap sector. These properties are held to provide the Company with a tangible asset base while management pursues its broader bio-pharmaceutical goals.

*Licensing and Regulatory Compliance*

Through its wholly-owned subsidiary, HEMP BioSciences Inc., the Company maintained its comprehensive suite of industrial hemp licenses in Arizona, including cultivation, nursery, and processing permits. Additionally, in late 2025, the Company successfully completed the de-registration of its non-essential international subsidiaries, WEED Hong Kong Ltd. and WEED Australia Ltd. This repatriation of assets and intellectual property to the U.S. parent company was a strategic move to reduce overhead and simplify the corporate governance structure.

This discussion and analysis should be read in conjunction with our financial statements included as part of this Quarterly Report.

---

| |
|:---|
| 21 |
| *[**Table of Contents**](#toc)* |

---

**Three Months Ended March 31, 2026 Compared to Three Months Ended March 31, 2025**

***Results of Operations***

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Revenue | $- | $- |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 67833 | 383268 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional fees | 90500 | 45847 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 5622 | 5622 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 163955 | 434737 |
| Net operating loss | (163955) | (434737) |
| Other income (expense) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (14099) | (5718) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation gain on dissolution of subsidiary | 2798 | - |
| Total other income (expense) | $(11301) | $(5718) |
| Income tax expense |  |  |
| Net Loss | $(175256) | $(440455) |
| Other Comprehensive Income (Loss) | - | 75 |
| Comprehensive Loss | $(175256) | $(440380) |

---

<u>Operating Loss; Net Loss</u>

Our comprehensive net loss decreased by $265,124, from $(440,380) to $(175,256), from the three months ended March 31, 2026, compared to the three months ended March 31, 2025. Our net operating loss decreased by $270,782 from $(434,737) to $(163,955) for the same period. The decrease in our comprehensive net loss and operating loss is primarily a result of decreases in general and administrative expenses and professional fees. These changes are detailed below.

<u>Revenue</u>

We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre's Cannabis Genomic Study and process those result. In the long-term we plan to be a company focused on purchasing land and building commercial grade "Cultivation Centers" to consult, assist, manage & lease to licensed dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana (Cannabis) sector. Our long-term plan is to become a True "Seed-to-Sale" company providing infrastructure, financial solutions and real estate options in this new emerging market, worldwide. We plan to make our brand global and therefore we will look for opportunities to conduct future research, marketing, import and exporting, and manufacturing of any proprietary products on an international level.

<u>General and Administrative Expenses</u>

General and administrative expenses decreased by $315,435, from $383,268 for the three months ended March 31, 2025, to $67,833 for the three months ended March 31, 2026, primarily due to decreases in our consulting services and salary.

---

| |
|:---|
| 22 |
| *[**Table of Contents**](#toc)* |

---

<u>Professional Fees</u>

Our professional fees increased by $44,653 during the three months ended March 31, 2026, compared to the three months ended March 31, 2025. Our professional fees were $90,500 for the three months ended March 31, 2026, and $45,847 for the three months ended March 31, 2025. These fees are largely related to fees paid for legal and accounting services, along with compensation to independent contractors. We expect these fees to vary quarter-to-quarter as our business and stock price fluctuate if we continue to use stock-based compensation. In the event we undertake an unusual transaction, such as an acquisition, securities offering, or file a registration statement, we would expect these fees to substantially increase during that period.

<u>Depreciation and Amortization</u>

During the three months ended March 31, 2026, we had depreciation and amortization expense of $5,622, compared to $5,622 in the three months ended March 31, 2025. Our depreciation and amortization expense primarily relates to our property and trademark acquisitions.

<u>Interest Expense</u>

Interest expense increased from $(5,718) for the three months ended March 31, 2025, to $(14,099) for the three months ended March 31, 2026. Our interest expense primarily relates to notes payable from related parties.

***Liquidity and Capital Resources***

**<u>Introduction</u>**

During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our cash needs from our revenues for many years to come.

---

| |
|:---|
| 23 |
| *[**Table of Contents**](#toc)* |

---

Our cash, current assets, total assets, current liabilities, and total liabilities as of March 31, 2026, and December 31, 2025, respectively, are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **March 31,** <br>**2026** | **December 31,**<br>**2025** | **Change** |
| Cash | $1795 | $33130 | $(31335) |
| Total Current Assets | 12365 | 47705 | (35340) |
| Total Assets | 515713 | 559906 | (44193) |
| Total Current Liabilities | 1353240 | 1248267 | 104973 |
| Total Liabilities | $1353240 | $1248267 | $104973 |

---

Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.

Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.

In order to pay our obligations in full or in part when due, we will be required to raise capital from other sources. There is no assurance, however, that we will be successful in these efforts.

<u>Cash Requirements</u>

We had cash available of $1,795 and $33,130 as of March 31, 2026 and December 31, 2025, respectively. Based on our lack of revenues, our cash on hand and current monthly burn rate of approximately $12,000, we will need to continue borrowing from our shareholders and other related parties, and/or raise money from the sales of our securities, to fund operations.

<u>Sources and Uses of Cash</u>

*Operations*

We had net cash used in operating activities of $57,737 for the three months ended March 31, 2026, as compared to $71,838 for the three months ended March 31, 2025. For the period in 2026, the net cash used in operating activities consisted primarily of our net loss of $(175,256), adjusted by depreciation and amortization of $5,622, debt discount amortization of $2,564, estimated fair value of shares issued for services of $26,400 and imputed interest of $2,488, respectively, and accrued expenses of $73,412. For the period in 2025, the net cash used in operating activities consisted primarily of our net loss of $(440,455), adjusted by depreciation and amortization of $5,622, debt discount amortization of $2,563, estimated fair value of stock based compensation and shares issued for services of $300,000 and $15,000, respectively, and further adjusted by accrued expenses of $(44,456).

*Investments*

For the three months ended March 31, 2026 and 2025, we had no cash flows provided from investing activities.

*Financing*

Our net cash used in financing activities for the three months ended March 31, 2026, was $(29,200), compared to $84,300 for the three months ended March 31, 2025. For the period in 2026, our financing activities related to proceeds of note payable of $30,000, offset by repayments of notes payable-related party of $(800). For the period in 2025, our financing activities related to proceeds of note payable of $45,700, offset by repayments of notes payable-related party of $(130,000).

---

| |
|:---|
| 24 |
| *[**Table of Contents**](#toc)* |

---

**Off Balance Sheet Arrangements**

We have no off-balance sheet arrangements.

**ITEM 3 Quantitative and Qualitative Disclosures About Market Risk**

As a smaller reporting company, we are not required to provide the information required by this Item.

**ITEM 4 Controls and Procedures**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a) Evaluation of Disclosure Controls Procedures**

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Disclosure and control procedures are also designed to ensure that such information is accumulated and communicated to management, including the chief executive officer and chief financial officer, to allow timely decisions regarding required disclosures.

As of March 31, 2026, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer, our Principal Executive Officer, and chief financial officer, our Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. In designing and evaluating disclosure controls and procedures, management recognizes that there are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their desired control objectives. Additionally, in evaluating and implementing possible controls and procedures, management is required to apply its reasonable judgment.

We also do not have an audit committee. Based on the evaluation described above, and as a result, in part, of not having an audit committee, having one individual serve as both our chief executive officer and chief financial officer, and the deficiencies previously reported, management concluded that, as of March 31, 2026, our disclosure controls and procedures were not effective.

In addition to the deficiencies previously reported, we do not have formal processes related to the identification, review, and approval of related party transactions.

As funds become available to us, we expect to implement additional measures to improve our disclosure controls and procedures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b) Changes in Internal Control over Financial Reporting**

There was no change in our internal control over financial reporting that occurred during the quarter ended March 31, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c) Officer's Certifications**

Appearing as exhibits to this quarterly report on Form 10-Q are certifications of our Chief Executive Officer and Chief Financial Officer. The certifications are required pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. This section of the quarterly report on Form 10-Q contains information concerning the controls evaluation referred to in the Section 302 certifications. This information should be read in conjunction with the Section 302 certifications for a more complete understanding of the topics presented.

---

| |
|:---|
| 25 |
| *[**Table of Contents**](#toc)* |

---

**PART II - OTHER INFORMATION**

**ITEM 1 Legal Proceedings**

In the ordinary course of business, we are from time to time involved in various pending or threatened legal actions. The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon our financial condition and/or results of operations. However, in the opinion of our management, other than as set forth herein, matters currently pending or threatened against us are not expected to have a material adverse effect on our financial position or results of operations.

**ITEM 1A Risk Factors**

As a smaller reporting company, we are not required to provide the information required by this Item.

**ITEM 2 Unregistered Sales of Equity Securities and Use of Proceeds**

During the period ended March 31, 2026, we issued the following unregistered securities:

<u>Common Stock Sales</u>

We did not sell any shares of our common stock during the period ended March 31, 2026.

<u>Common Stock Issued</u>

During the period ended March 31, 2026, 880,000 shares of common stocks valued at $26,400 were issued for the services.

**ITEM 3 Defaults Upon Senior Securities**

There have been no events which are required to be reported under this Item.

**ITEM 4 Mine Safety Disclosures**

There have been no events which are required to be reported under this Item.

**ITEM 5 Other Information**

None.

---

| |
|:---|
| 26 |
| *[**Table of Contents**](#toc)* |

---

**ITEM 6 Exhibits**

---

| | |
|:---|:---|
| **Item No.** | **Description** |
| [3.1 (1)](http://www.sec.gov/Archives/edgar/data/1393772/000165495417007371/exhibit_3-1.htm) | [Articles of Incorporation of WEED, Inc.](http://www.sec.gov/Archives/edgar/data/1393772/000165495417007371/exhibit_3-1.htm) |
| [3.2 (1)](http://www.sec.gov/Archives/edgar/data/1393772/000165495417007371/exhibit_3-2.htm) | [Bylaws of WEED, Inc.](http://www.sec.gov/Archives/edgar/data/1393772/000165495417007371/exhibit_3-2.htm) |
| [10.1 (1)](http://www.sec.gov/Archives/edgar/data/1393772/000165495417007371/exhibit_10-4.htm) | [Share Exchange Agreement by and between WEED, Inc. and Sangre AT, LLC dated April 20, 2017](http://www.sec.gov/Archives/edgar/data/1393772/000165495417007371/exhibit_10-4.htm) |
| [10.2 (1)](http://www.sec.gov/Archives/edgar/data/1393772/000165495417007371/exhibit_10-5.htm) | [Promissory Note dated July 26, 2017 issued to A.R. Miller for acquisition of La Veta, CO Property](http://www.sec.gov/Archives/edgar/data/1393772/000165495417007371/exhibit_10-5.htm) |
| [10.3 (1)](http://www.sec.gov/Archives/edgar/data/1393772/000165495417007371/exhibit_10-6.htm) | [Deed of Trust dated July 26, 2017 related to acquisition of La Veta, CO Property](http://www.sec.gov/Archives/edgar/data/1393772/000165495417007371/exhibit_10-6.htm) |
| [10.4 (2)](http://www.sec.gov/Archives/edgar/data/1393772/000165495417010830/exhibit_10-7.htm) | [Form of Securities Purchase Agreement](http://www.sec.gov/Archives/edgar/data/1393772/000165495417010830/exhibit_10-7.htm) |
| [10.5 (2)](http://www.sec.gov/Archives/edgar/data/1393772/000165495417010830/exhibit_10-8.htm) | [Form of Warrant Agreement](http://www.sec.gov/Archives/edgar/data/1393772/000165495417010830/exhibit_10-8.htm) |
| [10.6 (2)](http://www.sec.gov/Archives/edgar/data/1393772/000165495417010830/exhibit_10-9.htm) | [Purchase and Sale Agreement by and between WEED, Inc. and Greg DiPaolo's Pro Am Golf, LLC dated October 24, 2017](http://www.sec.gov/Archives/edgar/data/1393772/000165495417010830/exhibit_10-9.htm) |
| [10.7 (3)](http://www.sec.gov/Archives/edgar/data/1393772/000165495418000997/exhibit_10-10.htm) | [Amendment No. 1 to Promissory Note by and between WEED, Inc. and A.R. Miller dated January 12, 2018](http://www.sec.gov/Archives/edgar/data/1393772/000165495418000997/exhibit_10-10.htm) |
| [10.8 (3)](http://www.sec.gov/Archives/edgar/data/1393772/000165495418000997/exhibit_10-11.htm) | [Amended & Restated Employment Agreement with Glenn E. Martin dated February 1, 2018](http://www.sec.gov/Archives/edgar/data/1393772/000165495418000997/exhibit_10-11.htm) |
| [10.9 (3)](http://www.sec.gov/Archives/edgar/data/1393772/000165495418000997/exhibit_10-12.htm) | [Amended & Restated Employment Agreement with Nicole M. Breen dated February 1, 2018](http://www.sec.gov/Archives/edgar/data/1393772/000165495418000997/exhibit_10-12.htm) |
| [10.10 (3)](http://www.sec.gov/Archives/edgar/data/1393772/000165495418000997/exhibit_10-13.htm) | [Form of WEED, Inc. Restricted Stock Agreement](http://www.sec.gov/Archives/edgar/data/1393772/000165495418000997/exhibit_10-13.htm) |
| [10.11 (3)](http://www.sec.gov/Archives/edgar/data/1393772/000165495418000997/exhibit_10-14.htm) | [Form of WEED, Inc. Notice of Grant of Non-Qualified Stock Options](http://www.sec.gov/Archives/edgar/data/1393772/000165495418000997/exhibit_10-14.htm) |
| [10.12 (3)](http://www.sec.gov/Archives/edgar/data/1393772/000165495418000997/exhibit_10-15.htm) | [Wage Settlement and Release Agreement with Ryan Breen dated February 1, 2018](http://www.sec.gov/Archives/edgar/data/1393772/000165495418000997/exhibit_10-15.htm) |
| [10.13 (4)](http://www.sec.gov/Archives/edgar/data/1393772/000165495418004532/exhibit_10-16.htm) | [Second Addendum to Purchase and Sale Agreement Greg DiPaolo's Pro Am Gold, LLC dated February 19, 2018](http://www.sec.gov/Archives/edgar/data/1393772/000165495418004532/exhibit_10-16.htm) |
| [10.14 (5)](http://www.sec.gov/Archives/edgar/data/1393772/000165495419002365/exhibit_10-1.htm) | [Exclusive License and Assignment Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. dated March 1, 2019](http://www.sec.gov/Archives/edgar/data/1393772/000165495419002365/exhibit_10-1.htm) |
| [10.15 (5)](http://www.sec.gov/Archives/edgar/data/1393772/000165495419002365/exhibit_10-2.htm) | [Consulting Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. and Prof. Elka Touitou dated March 1, 2019](http://www.sec.gov/Archives/edgar/data/1393772/000165495419002365/exhibit_10-2.htm) |
| [10.16 (7)](http://www.sec.gov/Archives/edgar/data/1393772/000119983521000739/ex10-1.htm) | [Promissory Note issued by WEED, Inc. to Glenn E. Martin dated November 2, 2021](http://www.sec.gov/Archives/edgar/data/1393772/000119983521000739/ex10-1.htm) |
| [10.17 (8)](http://www.sec.gov/Archives/edgar/data/1393772/000119983522000450/budz-ex10_1.htm) | [Share Exchange Agreement with Hempirical Genetics, LLC dated May 2, 2022](http://www.sec.gov/Archives/edgar/data/1393772/000119983522000450/budz-ex10_1.htm) |
| [10.18 (8)](http://www.sec.gov/Archives/edgar/data/1393772/000119983522000450/budz-ex10_2.htm) | [Employment Agreement with Jeffery Miller dated May 2, 2022](http://www.sec.gov/Archives/edgar/data/1393772/000119983522000450/budz-ex10_2.htm) |

---

---

| |
|:---|
| 27 |
| *[**Table of Contents**](#toc)* |

---

---

| | |
|:---|:---|
| [21.1 (6)](http://www.sec.gov/Archives/edgar/data/1393772/000165495419004420/exhibit_21-1.htm) | [Subsidiaries of WEED, Inc.](http://www.sec.gov/Archives/edgar/data/1393772/000165495419004420/exhibit_21-1.htm) |
| [31.1](budz_ex311.htm) | [Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer (filed herewith).](budz_ex311.htm) |
| [31.2](budz_ex312.htm) | [Rule 13a-14(a)/15d-14(a) Certification of Chief Accounting Officer (filed herewith).](budz_ex312.htm) |
| [32.1](budz_ex321.htm) | [Section 1350 Certification of Chief Executive Officer (filed herewith).](budz_ex321.htm) |
| [32.2](budz_ex322.htm) | [Section 1350 Certification of Chief Accounting Officer (filed herewith).](budz_ex322.htm) |

---

---

| | |
|:---|:---|
| 101.INS \*\* | Inline XBRL Instance Document |
| 101.SCH \*\* | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL \*\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF \*\* | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB \*\* | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE \*\* | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104\*\* | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |

---

\* Filed herewith.

\*\* XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

(1) Incorporated by reference from our Registration Statement on Form S-1 filed with the Commission on August 11, 2017.

(2) Incorporated by reference from the Amendment No. 1 to our Registration Statement on Form S-1 filed with the Commission on November 16, 2017.

(3) Incorporated by reference from the Amendment No. 2 to our Registration Statement on Form S-1 filed with the Commission on February 1, 2018.

(4) Incorporated by reference from the Amendment No. 3 to our Registration Statement on Form S-1 filed with the Commission on April 30, 2018.

(5) Incorporated by reference from the Current Report on Form 8-K filed with the Commission on March 7, 2019.

(6) Incorporated by reference from the Annual Report on Form 10-K filed with the Commission on April 16, 2019.

(7) Incorporated by reference from the Current Report on Form 8-K filed with the Commission on December 10, 2021.

(8) Incorporated by reference from the Current Report on Form 8-K filed with the Commission on August 4, 2022.

---

| |
|:---|
| 28 |
| *[**Table of Contents**](#toc)* |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **WEED, Inc.** | **WEED, Inc.** |
| Dated: May 15, 2026 | By: | /s/ Glenn E. Martin |
|  |  | Glenn E. Martin |
|  | Its: | President, Chief Executive Officer (Principal Executive Officer), Chief Financial Officer (Principal Accounting Officer) (Principal Financial Officer) |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer**

I, Glenn E. Martin, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of WEED, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exhibit Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Dated: May 15, 2026 |  | /s/ Glenn E. Martin |
|  | By: | Glenn E. Martin |
|  |  | Chief Executive Officer |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer**

I, Glenn E. Martin, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of WEED, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exhibit Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting **.** 

---

| | | |
|:---|:---|:---|
| Dated: May 15, 2026 |  | /s/ Glenn E. Martin |
|  | By: | Glenn E. Martin |
|  |  | Chief Financial Officer and Principal Accounting Officer |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO 18 USC, SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906**

**OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of WEED, Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2026, as filed with the Securities and Exchange Commission on or about the date hereof (the "Report"), I, Glenn E. Martin, President of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Dated: May 15, 2026 |  | /s/ Glenn E. Martin |
|  | By: | Glenn E. Martin |
|  |  | Chief Executive Officer |

---

A signed original of this written statement required by Section 906 has been provided to WEED, Inc. and will be retained by WEED, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

## Exhibit 32.2

**EXHIBIT 32.2**

**CERTIFICATION PURSUANT TO 18 USC, SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906**

**OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of WEED, Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2026, as filed with the Securities and Exchange Commission on or about the date hereof (the "Report"), I, Glenn E. Martin, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Dated: May 15, 2026 |  | /s/ Glenn E. Martin |
|  | By: | Glenn E. Martin |
|  |  | Chief Financial Officer and Chief Accounting Officer |

---

A signed original of this written statement required by Section 906 has been provided to WEED, Inc. and will be retained by WEED, Inc. and furnished to the Securities and Exchange Commission or its staff upon request